Should I buy Pfizer stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring Pfizer’s performance for over three years. Each month, hundreds of thousands of Canadians trust us to interpret market trends and highlight the best investment opportunities. Our insights are intended for informational purposes only and do not represent investment advice. In line with our ethical charter, we have never been, and will never be, paid by Pfizer.

What is Pfizer?

How much is Pfizer stock?

The price of Pfizer stock is rising this week. As of now, Pfizer shares are trading at $24.25 USD, up 1.93% in the past 24 hours and showing a weekly gain of 8.35%. The company holds a market capitalization of $137.59 billion, with a three-month average daily volume of 52.46 million shares.

Pfizer’s current P/E ratio stands at 17.21, delivering a robust dividend yield of 7.23%, and features a stock beta of 0.60, indicating lower volatility compared to the overall market. This combination of strong income potential and moderate volatility may appeal to Canadian investors looking for stability and reliable returns.

Our full analysis on Pfizer stock

Having carefully examined Pfizer Inc.'s latest financial disclosures and assessed the stock’s trajectory over a turbulent three-year period, we have leveraged a proprietary blend of financial metrics, advanced technical analysis, market sentiment data, and peer benchmarking to conduct a holistic review of PFE. Our multi-source approach offers a dynamic perspective on a globally influential healthcare giant. So, why might Pfizer stock once again become a strategic entry point into the healthcare and pharmaceutical sector for Canadian and international investors looking toward 2025?

Recent Performance and Market Context

Pfizer's journey over the last twelve months reflects both the challenges and the resilience inherent to leaders in the global pharmaceutical industry. After experiencing pandemic-driven highs, PFE has recalibrated, now trading at $24.25 as of April 30, 2025. This places it near the lower end of its 52-week range ($20.92 - $31.54), a level historically attractive to value-oriented investors.

Over the past week, momentum has clearly accelerated (+8.35%), suggesting investor sentiment is shifting following first-quarter results and optimistic management guidance. Short-term performance stands in vivid contrast to the 6-month and year-to-date negative returns (-14.94% and -8.56%, respectively), indicating a potential inflection point. The recent uptick is especially notable, considering Pfizer’s market capitalization remains robust at $137.59 billion, ensuring its role as a defensive sector cornerstone.

On the positive side, macroeconomic fundamentals for healthcare remain supportive. Population aging, chronic disease prevalence, and increasing demand for innovative treatments create a significant runway for global pharmaceuticals. Within its competitive set, Pfizer’s scale and diversification act as vital buffers—particularly relevant against current industry headwinds such as post-pandemic normalization and U.S. regulatory developments.

Technical Analysis

A nuanced technical picture emerges for PFE. The short-term landscape is encouraging: the price currently sits above its 5-day ($22.99) and 20-day ($22.76) moving averages, each sending a buy signal and supporting an emerging bullish reversal. This prevalence of short-term technical strength is reinforced by the recent strong bounce off established support levels ($22.87, $22.69, $22.48), with price action decisively reclaiming ground abandoned earlier in the year.

Momentum oscillators, such as the Relative Strength Index (RSI 14) at 53.95, underline a neutral-to-bullish bias—well away from both overbought and oversold thresholds, granting latitude for further appreciation. While the MACD registers slightly negative (-0.50), this appears to reflect longer-term price action lagging the more immediate market turnaround, a dynamic often preceding upward price correction for fundamentally attractive equities.

Medium- and long-term technical structure remains more cautious, with PFE trading below its 50-day ($24.71), 100-day ($25.30), and 200-day ($26.51) moving averages. Such configuration often defines a stock in transition, with persistent value compression but clear potential for a mean-reversion rally once quarterly catalysts and cost-cutting initiatives influence earnings outlooks. Strong support levels have been repeatedly validated, and a break above resistance ($23.65, $24.10) could confirm entry into a new bullish phase, providing clear technical targets for both traders and long-term investors.

Fundamental Analysis

Pfizer’s intrinsic value proposition stands out firmly. Reporting Q1 2025 revenues of $13.7 billion and net income of $2.97 billion, the company signaled robust underlying profitability despite an 8% year-over-year revenue decline. The adjusted diluted EPS of $0.92 exceeded market consensus, and management’s reaffirmation of 2025 guidance ($61.0-$64.0 billion in revenues; $2.80-$3.00 in EPS) provides ground for renewed investor confidence.

• Vyndaqel family: +33% (cardiac amyloidosis)
• Comirnaty (COVID-19 vaccine): +62%
• Padcev (oncology): +25%
• Nurtec ODT/Vydura (migraine): +40%
• Lorbrena (oncology): +39%

Such performance illustrates strategic resilience—all the more impressive given industry-wide headwinds and normalized COVID-related product sales.

• Forward P/E of 8.09: Considerably below both sector averages and Pfizer’s historic norms, indicating the market is pricing in a cautious scenario that may already capture most of the downside risks.
• Price/Sales of 2.13 and Price/Book of 1.53: Both sit at notable discounts to peer group medians.
• Enterprise Value/EBITDA of 9.82 and a dividend yield above 7% further solidify the case for income-oriented investors.

Structural strengths—global brand equity, a diversified pipeline and product portfolio, and a powerful R&D engine ($2.2 billion invested in Q1 2025 alone)—support a compelling growth narrative. The company’s operational optimization (with more than $4.5 billion in savings targeted by end of 2025) strongly positions Pfizer to capitalize on both existing blockbusters and impending pipeline launches.

Volume and Liquidity

From a trading perspective, Pfizer’s liquidity is indisputable. An average daily volume of 52.46 million shares assures ample market depth and price transparency, an important consideration for institutional and high-net-worth investors alike. Significant float and consistent trading activity mitigate liquidity risk, fostering dynamic valuation adjustment and setting the stage for efficient entrance and exit strategies by various investor types.

Such sustained volume, particularly during recent price surges, often suggests renewed market confidence and serves as a leading indicator of enduring investor interest. It is a profile consistent with stocks poised for volatility-driven upward rerating.

Catalysts and Positive Outlook

Looking at the next twelve months, multiple catalysts may underpin a sustained recovery and re-rating for Pfizer’s stock:

• Best-in-class dividend: A yield of 7.23% places PFE at the pinnacle of large-cap pharma income plays, likely attracting yield-focused, defensive capital allocations in a high-rate environment.
• Cost transformation program: Delivering up to $5.7 billion total cost savings by end of 2027, management’s operational optimization efforts are expected to materially expand margins and free up capital for both R&D and shareholder returns.
• Pipeline momentum: Multiple high-growth assets (Vyndaqel, Padcev, Lorbrena, and migraine franchises) continue to exhibit double-digit traction, while near-commercial-stage assets could drive incremental sales growth.
• ESG and innovation: Substantial reinvestment of savings into R&D signal commitment to innovation, crucial for long-term differentiation amid generic and biosimilar competition. Not least, robust ESG credentials further enhance long-term fund appeal.
• Analyst price target of $29.34: This target — implying more than 20% upside potential — reflects the consensus that Pfizer is undervalued at current levels given the likely impact of initiatives undertaken.

Macro factors, including a resilient healthcare spending environment, demographic tailwinds, and regulatory clarity in key markets, all further support a favorable context for significant capital appreciation.

Investment Strategies

Given the technical and fundamental alignment, several strategic approaches could be considered:

• Short-term positioning:
• Technical bounce above immediate support levels can be leveraged for tactical exposure, particularly as price momentum surges on improved Q1 results and pre-dividend capture strategies ahead of the ex-dividend date (May 9, 2025).
• Short-term bullish structure supports opportunistic entry for momentum traders seeking a rapid move back to 50-day moving average resistance ($24.71).
• Medium-term entry:
• Those eyeing 3-12 month horizons will note the compelling entry near the low end of the 52-week range, with cost optimization and pipeline data readouts expected as progressive catalysts.
• Ongoing R&D milestones, mid-year results, and further evidence of operational efficiency present opportunities for valuation uplift.
• Long-term portfolio anchor:
• For dividend growth and conservative investors, current valuations combined with strategic cost savings, a robust pipeline, and reliable yield represent an attractive “buy and hold” thesis.
• The stock’s position as a global leader with low beta (0.60), strong cash generation, and reinvestment in sustainable growth suggest resilience through economic cycles and competitive waves.

Is it the Right Time to Buy Pfizer?

Pfizer’s current risk/reward profile seems to represent an excellent opportunity for investors ready to take advantage of sector volatility and harvest a defensive, income-generating yield. Reinforced by a recalibrated valuation, aggressive cost management, breakthrough growth from key products, and the prospect for margin expansion, the fundamentals justify renewed interest. The convergence of technical reversal signals and undervalued financial metrics present in PFE’s setup may well indicate the start of a new bullish phase, particularly as management guidance grows increasingly confident.

While risks—particularly regulatory and competitive—remain, Pfizer’s unique blend of stability, innovation, and value positions it as a prime candidate for serious consideration in 2025 portfolios. With robust liquidity, clear catalysts on the horizon, and consensus upside potential, the timing appears favorable for those seeking exposure to a global healthcare leader on the verge of resurgence.

In today’s market environment, Pfizer’s combination of value, income, and growth prospects makes it a standout consideration for investors seeking to capitalize on a sector giant poised for recovery and long-term compounding.

How to buy Pfizer stock in Canada?

Buying Pfizer stock online in Canada is a straightforward and secure process when you use a regulated broker. Modern online platforms let retail investors purchase shares or trade via contract for difference (CFD), both offering efficient and user-friendly interfaces. With spot (cash) buying, you own real shares and can receive dividends, while CFDs let you speculate on price movements using leverage—though you do not actually own the underlying shares. Both methods are widely available to Canadian residents. To help you choose the right option, you’ll find a broker comparison further down this page.

Spot Buying (Cash Purchase)

A cash purchase means you buy actual Pfizer shares on the New York Stock Exchange (NYSE) in your brokerage account. You become a shareholder, with the potential to earn dividends—like Pfizer’s attractive 7.23% yield. Most Canadian brokers charge a fixed commission per order, often between $5 and $10 CAD.

Example

For example, if Pfizer’s share price is $24.25 USD (about $33 CAD), with $1,000 CAD (after a $5 fee), you could buy approximately 29 shares.

Gain scenario: If Pfizer shares rise by 10%, your holding becomes worth about $1,100 CAD. Result: +$100 gross gain, or +10% on your initial investment.

Trading via CFD

With CFDs (Contracts for Difference), you can trade Pfizer’s price movements without owning the actual shares. CFDs allow you to use leverage—potentially amplifying gains and losses. Typical CFD costs include the spread (difference between buy and sell price) and overnight financing fees for holding leveraged positions. For instance, with $1,000 CAD and 5x leverage, your market exposure would be $5,000 CAD.

Example

Gain scenario: If Pfizer’s price increases by 8%, your CFD position would generate a 40% gain—$400 CAD on your $1,000 stake (excluding fees).

Final Advice

Before you invest, it’s essential to compare broker fees, currency conversion rates, and platform conditions. Your best option will depend on whether you want to own shares for the long term and receive dividends (spot buying), or if you prefer to trade short-term price movements with leverage (CFDs). Explore the detailed broker comparison below to find the platform that best matches your investing goals and experience level.

Platforms

Minimum Deposit

Discover

#1

Tier 1 regulation, including ASIC and FSA

#1

Star Trader

4.9

Minimum Deposit

$50

Discover

with our partner Star Trader

#2

Broker specializing in Forex and CFDs

#2

IFC Markets

4.8

Minimum Deposit

$1

Discover

with our partner IFC Markets

#3

Broker regulated since 2006

#3

Avatrade

4.8

Minimum Deposit

$100

Discover

with our partner Avatrade

Our 7 tips for buying Pfizer stock

The latest news about Pfizer

Pfizer's robust Q1 2025 earnings report sparks strong stock rebound, with an 8.35% weekly gain. On April 29, 2025, Pfizer released first-quarter results that exceeded market expectations for adjusted earnings per share ($0.92) and offered reassurance by stating it is trending towards the upper end of its annual EPS guidance range. Notably, revenue declines were partially offset by substantial operational growth in key products such as the Vyndaqel family (+33%) and Comirnaty COVID-19 vaccine (+62%), which are both distributed and promoted within Canada, further solidifying its reputation and market presence regionally. This positive financial momentum contributed to an intraday stock price surge of nearly 2% and has driven Pfizer shares to outperform major pharmaceutical peers over the last week, which is likely to be positively received by Canadian institutional investors seeking stability and income.

Pfizer’s 7.23% dividend yield stands out for Canadian income investors amid ex-dividend date proximity. With a declared annual dividend of $1.72 and an ex-dividend date set for May 9, 2025, Pfizer offers one of the most attractive yields in the large-cap pharma segment. This feature is particularly relevant for Canadian residents seeking U.S. stock exposure with a focus on reliable income streams, given Pfizer’s uninterrupted dividend payout record. Additionally, Canadian investors may benefit from favourable tax treaties on qualified U.S. dividends, further enhancing after-tax returns compared to domestic alternatives.

Pfizer accelerates cost optimization measures and R&D investment, reaffirming long-term local and global commitments. The company reported significant progress on its cost realignment strategy, targeting $4.5 billion in net savings by year-end and an additional $1.2 billion by 2027, while simultaneously investing $2.2 billion in R&D during Q1. A dedicated portion of these savings is set to be reinvested into building Pfizer’s drug pipeline, underscoring ongoing partnerships with Canadian research institutions and clinical trial networks. This dual focus on operational efficiency and innovation resonates with Canadian stakeholders—both as customers and as R&D partners—helping sustain a vibrant biopharmaceutical ecosystem locally.

Technical signals suggest short-term bullish momentum, with Pfizer trading above key short-term moving averages. Recent technical analysis reveals Pfizer shares have moved above their 5-day and 20-day moving averages, generating buy signals for short-term traders. While longer-term trends remain bearish with the stock below its 50-day, 100-day, and 200-day averages, the current neutral RSI and a recent 8.35% weekly increase highlight renewed market interest and the potential for continued short-term rallies. Canadian traders and portfolio managers may interpret these trends as tactical entry points, especially for those seeking to hedge domestic healthcare holdings or diversify sector exposures.

The Canadian healthcare sector remains strategically important to Pfizer, reinforced by ongoing product launches and regulatory achievements. Pfizer’s operations across Canada are supported by continued collaboration with Health Canada around product approvals and post-pandemic vaccine distribution. Key growth franchises—including oncology, rare cardiology drugs, and expanded vaccine offerings—ensure that Canadians remain among the first beneficiaries of Pfizer’s innovation pipeline. These initiatives reinforce both revenue visibility and brand prestige in the local market, which can help foster sustained investor confidence north of the border.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.